Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
Methods for predicting a therapeutic response in a patient (e.g., a cancer patient) to ErbB3 inhibitors, and methods of treating a cancer patient with targeted therapies.
1. A method of treating a patient having a heregulin positive (HRG+) cancer with a solid tumor having a ratio of expressed ErbB4 to ErbB3 of less than 1.3, wherein the expressed ErbB4 and ErbB3 are each detected by RNA in situ hybridization (RNA-ISH) or by RT-PCR, the method comprising: administering a therapeutically effective amount of an anti-ErbB3 antibody to the patient, wherein the anti-ErbB3 antibody comprises CDRH1, CDRH2, and CDRH3 sequences comprising the amino acid sequences set forth in SEQ ID NO:1 (CDRH1), SEQ ID NO:2 (CDRH2), and SEQ ID NO:3 (CDRH3); and CDRL1, CDRL2, and CDRL3 sequences comprising the amino acid sequences set forth in SEQ ID NO:4 (CDRL1), SEQ ID NO:5 (CDRL2), and SEQ ID NO:6 (CDRL3).
2. The method of claim 1 , wherein the tumor is a NSCLC tumor.
3. The method of claim 1 , wherein the tumor is a melanoma tumor.
4. The method of claim 1 , wherein the tumor is a breast tumor.
5. The method of claim 1 , wherein the tumor is an ovarian tumor.
6. The method of claim 1 , wherein the tumor is platinum-resistant or refractory.
7. The method of claim 1 , wherein the anti-ErbB3 antibody is seribantumab.
8. A method of treating a patient diagnosed with a heregulin positive (HRG+) solid tumor having a ratio of expressed ErbB4 to ErbB3 of less than 1.3, wherein the expressed ErbB4 to ErbB3 are each detected by RNA in situ hybridization (RNA-ISH) or by RT-PCR, the method comprising: administering a therapeutically effective amount of an anti-ErbB3 antibody to the patient, wherein the anti-ErbB3 antibody comprises CDRH1, CDRH2, and CDRH3 sequences comprising the amino acid sequences set forth in SEQ ID NO:1 (CDRH1), SEQ ID NO:2 (CDRH2), and SEQ ID NO:3 (CDRH3); and CDRL1, CDRL2, and CDRL3 sequences comprising the amino acid sequences set forth in SEQ ID NO:4 (CDRL1), SEQ ID NO:5 (CDRL2), and SEQ ID NO:6 (CDRL3).
9. The method of claim 8 , wherein the cancer is NSCLC.
10. The method of claim 8 , wherein the cancer is melanoma.
11. The method of claim 8 , wherein the cancer is breast cancer.
12. The method of claim 8 , wherein the cancer is an ovarian cancer.
13. The method of claim 8 , wherein the anti-ErbB3 antibody is seribantumab.
14. A method of treating a patient diagnosed with a cancer selected from the group consisting of: non-small cell lung cancer (NSCLC), melanoma, breast cancer, and ovarian cancer, the cancer having a heregulin positive (HRG+) solid tumor having a ratio of expressed ErbB4 to ErbB3 of less than 1.3, wherein the expressed ErbB4 and ErbB3 are each detected by RNA in situ hybridization (RNA-ISH) or by RT-PCR, and the method comprises administering a therapeutically effective amount of seribantumab to the patient.
15. The method of claim 14 , wherein the breast cancer is a HRG+, ER+, PR+ and HER2 negative breast cancer.
16. The method of claim 14 , wherein the cancer is a NSCLC cancer.
17. The method of claim 14 , wherein the cancer is an ovarian cancer.
18. The method of claim 14 , wherein the cancer is a melanoma cancer.